AGI-5198

CAS No. 1355326-35-0

AGI-5198 ( (IDH-C35) )

Catalog No. M11453 CAS No. 1355326-35-0

AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 32 In Stock
10MG 29 In Stock
25MG 37 In Stock
50MG 43 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AGI-5198
  • Note
    Research use only, not for human use.
  • Brief Description
    AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
  • Description
    AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    (IDH-C35)
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    R132C-IDH1| R132H-IDH1
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1355326-35-0
  • Formula Weight
    462.57
  • Molecular Formula
    C27H31FN4O2
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 14 mg/mL (30.26 mM); DMSO: 24 mg/mL (51.88 mM)
  • SMILES
    O=C(NC1CCCCC1)C(N(C2=CC=CC(F)=C2)C(CN3C=CN=C3C)=O)C4=CC=CC=C4C
  • Chemical Name
    N-cyclohexyl-2-(N-(3-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido)-2-(o-tolyl)acetamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Rohle D, et al. Science, 2013, 340(6132), 626-630.
molnova catalog
related products
  • Mutant IDH1 inhibito...

    Mutant IDH1 inhibitor is an effective inhibitor of mutant IDH1 R132H (IC50: < 72 nM).

  • WAY-324168

    WAY-324168 is a compound with antiproliferative activity.

  • Dovitinib Dilactic A...

    Dovitinib Dilactic acid (TKI258 Dilactic acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor.